A Study to Evaluate LY06006 and Prolia in Healthy Adults
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, parallel-group study in Chinese healthy male subjects to evaluate
the pharmacokinetics, pharmacodynamics, safety and immunogenicity of LY06006 versus Prolia
following single-dose subcutaneous injection